Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. freshman Avg
|
New words:
absorb, acco, administered, advantage, af, affil, affiliati, AGHD, alefacept, allergy, Amevive, antigen, arena, ASH, autoimmunity, bad, Bayer, Biogen, biogeneric, bovine, BSE, caption, ce, Celltech, ch, channel, charter, CLL, code, COH, colon, compara, confidential, Congressional, contami, contamination, convict, coordination, Cosmetic, coupled, criminal, cyclosporin, detail, detailed, Developmen, diagnosed, diffuse, dimerization, diminished, driver, DSO, ECOG, elated, element, ement, emplo, encephalopathy, endothelial, enforcing, epending, evolving, exemplary, expertise, exploring, factory, feature, feel, fermentation, filiation, fo, FOLFOX, foregoi, frame, fraud, fringe, fro, front, GAAP, GH, GHD, glioblastoma, Hampshire, healing, hedgehog, heet, highest, iation, ich, IIb, illion, immunological, Immunology, inability, indefinite, indolent, inimum, installed, investee, IRS, iv, lab, lending, lent, Leucovorin, Levinso, light, Lonza, magnitude, meaningful, Medicaid, Medicare, methotrexate, minimal, minimize, Modernization, modification, modulator, monotherapy, multiforme, network, newer, newly, ng, nonrecourse, Nonrefundable, noti, Obli, observed, obsolete, OCI, Omnitarg, onetary, online, opera, opted, outlook, ovarian, owever, Oxaliplatin, pace, peanut, peripheral, persistent, pertuzumab, phototherapy, physician, plase, Portsmouth, pre, predominantly, priority, prod, prompt, prostate, prudent, psoriatic, punishable, purest, ramped, reallege, recla, recourse, recruiting, rectum, Redwood, regimen, reincorporated, rendered, Rental, rev, rounding, salary, Saltz, sBLA, scrutiny, Seventeen, slowdown, sNDA, soluble, spongiform, ss, ssified, strive, super, supplier, suret, tenecte, territory, timeframe, titled, TNF, Tria, ultraviolet, unclear, undelivered, unique, unle, unrestricted, unting, untreated, urth, VIE, vigorously, viously, warehouse, weight, wh, withdraw, wound, Wyeth, yee
Removed:
Actilyse, actimmune, artery, Boehringer, bowel, BTG, Canadian, competitor, constructed, coronary, CuraGen, designation, dissolve, Eli, enjoined, enzyme, feet, gamma, Genotropin, GmbH, GRTPA, Hakko, infringed, Ingelheim, interferon, Kogyo, Kyowa, letter, Lilly, Mitsubishi, monoclonal, naturally, Nordisk, Novo, Orphan, people, rapidly, recently, redeemable, registrant, scheduled, square, Sumitomo, symptom, Washington
Filing tables
Filing exhibits
- 10-K Annual report
- 10.10 1991 Employee Stock Plan, As Amended on April 23, 2003.
- 10.16 Amended and Restated Backup Facility Agreement and Amendment to Other Operative Agreements, Dated As of November 6, 2003, Among Dna Finance Corp, JP Morgan Bank and Various Financial Institutions Named Therein.
- 23.1 Consent of Ernst & Young LLP, Independent Auditors.
- 31.1 Certification of Chief Executive Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended.
- 31.2 Certification of Chief Financial Officer Pursuant to Rules 13A-14(A) and 15D-14(A) Promulgated Under the Securities Exchange Act of 1934, As Amended.
- 32.1 Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002.
Genentech similar filings
Filing view
External links